能否Endothelin-1成为急性心力衰竭中一个有前途的神经激素生物标志物?
Bianca-Ana Dmour1, Alexandru Dan Costache1,2, Awad Dmour3,4
1Department of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iași, Romania.
Diagnostics (Basel, Switzerland)
|July 14, 2023
概括
内甲素-1 (ET-1) 在急性心力衰竭 (AHF) 发病过程中起着关键作用. 研究表明,ET-1可能成为改善AHF诊断和患者管理的有价值生物标志物.
科学领域:
- 心脏病学 心脏病学
- 生物标志物研究 生物标志物研究
背景情况:
- 急性心力衰竭 (AHF) 带来了重大的诊断和预后挑战.
- 有效的AHF管理依赖于准确的临床判断,得到可靠生物标志物的支持.
研究的目的:
- 在AHF的背景下,审查当前关于内甲素-1 (ET-1) 的研究.
- 评估ET-1作为AHF有前途的生物标志物的潜力.
主要方法:
- 在AHF中调查ET-1的研究的文献综述.
- 分析ET-1在AHF病原和临床关联中的作用.
主要成果:
- ET-1涉及多种AHF通路,包括神经激素激活,心脏重塑和内皮功能障碍.
- 升高的ET-1水平与AHF症状严重程度和心脏功能障碍相关.
结论:
- 内甲素-1 (ET-1) 是一个关键的神经激素,参与AHF.
- ET-1显示出作为一种有价值的生物标志物的潜力,可以提高AHF诊断和患者护理.
相关概念视频
Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
121
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
121
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
202
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
202
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14


